Previous close | 1.3100 |
Open | 1.2900 |
Bid | 1.2300 x 300 |
Ask | 1.2800 x 400 |
Day's range | 1.2000 - 1.3004 |
52-week range | 0.7700 - 14.0000 |
Volume | |
Avg. volume | 2,754,849 |
Market cap | 5.27M |
Beta (5Y monthly) | 1.41 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Here is how Masimo (MASI) and Adial Pharmaceuticals, Inc. (ADIL) have performed compared to their sector so far this year.
Adial Pharmaceuticals, Inc. (ADIL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Adial (ADIL) shares rise 43% in the past week after the company announced positive regulatory updates on its only pipeline candidate, AD04, for the treatment of alcohol use disorder.